Chris Sharp, founder of Skye Biologics, has spent more than 20 years advancing medtech and biotech in the musculoskeletal arena by developing clinically relevant spine and orthopedic implants to augment damaged tissue and provide structural support. More recently, he has focused on developing placental tissue therapies designed to assist in repair and remodeling in orthopedics, sports medicine, spine, chronic wounds and many degenerative conditions, recognizing the untapped potential and unmet surgical need to help physicians solve biologic challenges beyond their control.
Sharp has led Skye Biologics to treat over 600,000 patients and build one of the industry's most diverse portfolios of naturally derived allograft products. His focus on scientific rigor, clinical observation, and physician insight has positioned Skye Biologics as a leader over the last decade in placental-derived implants and set new benchmarks for progress in the field. Our goal with the next-generation products under development is to help doctors find a hack to help with their patient's biological issues and challenges that have eluded them up until now..
